| 摘要 |
<p>The present invention relates to novel crystalline forms of rivaroxaban, in particular, rivaroxaban of formula (I) in the crystalline form B1, the crystalline form B2, and crystalline form E. It also relates to a process of preparing said polymorphic forms and their conversion into other crystalline forms.</p> |
